Mark Zorbas
Impact in
- Virology top 10%
- HIV Research and Treatment
-
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
Papers in
- Oncology 7
- HER2/EGFR in Cancer Research 3
-
- Retinoids in leukemia and cellular processes 2
- Co-authors
- Lynn C. Yeoman (5 shared papers)David L. Shelton (7 shared papers)Susan Hurst (6 shared papers)Gary E. Gallick (3 shared papers)Stephanie Webber (7 shared papers)Bhasker V. Shetty (3 shared papers)Matilde Olivé (2 shared papers)Mark T. Butt (5 shared papers)
- Journals
- Regulatory Toxicology and Pharmacology (3 papers)Toxicological Sciences (2 papers)Human & Experimental Toxicology (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)Drug Metabolism and Disposition (1 paper)
- Partner nations
- United StatesAustraliaDenmark
In The Last Decade
Mark Zorbas
25 papers receiving 454 citations
Peers
Comparison fields: 5 of 78
- Virology 37
- Infectious Diseases 86
- Oncology 109
- Cellular and Molecular Neuroscience 58
- Small Animals 23
Countries citing papers authored by Mark Zorbas
This map shows the geographic impact of Mark Zorbas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Zorbas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Zorbas more than expected).
Fields of papers citing papers by Mark Zorbas
This network shows the impact of papers produced by Mark Zorbas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Zorbas. The network helps show where Mark Zorbas may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Zorbas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2001 | 109 | |
| 2 | Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. | 1991 | 76 |
| 3 | 2016 | 46 | |
| 4 | Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. | 2000 | 36 |
| 5 | Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene. | 1993 | 31 |
| 6 | 2017 | 27 | |
| 7 | 2010 | 25 | |
| 8 | 2014 | 20 | |
| 9 | 1993 | 13 | |
| 10 | 2005 | 13 | |
| 11 | 2014 | 13 | |
| 12 | 1993 | 11 | |
| 13 | 2018 | 9 | |
| 14 | Transferrin and insulin enhance human colon tumor cell growth by differentiation class specific mechanisms. | 1996 | 9 |
| 15 | 2013 | 9 | |
| 16 | 2016 | 5 | |
| 17 | 2003 | 3 | |
| 18 | 2003 | 3 | |
| 19 | 2004 | 3 | |
| 20 | 2005 | 2 |
About Mark Zorbas
Mark Zorbas is a scholar working on Oncology, Molecular Biology, Physiology, Infectious Diseases and Cellular and Molecular Neuroscience, having authored 25 papers that have together received 470 indexed citations. Recurring topics across this work include Pain Mechanisms and Treatments (6 papers), HIV/AIDS drug development and treatment (5 papers), HER2/EGFR in Cancer Research (3 papers), HIV Research and Treatment (3 papers), Youth Education and Societal Dynamics (2 papers), Neuroscience and Neuropharmacology Research (2 papers), Retinoids in leukemia and cellular processes (2 papers) and HIV/AIDS Research and Interventions (2 papers). The work is most often cited by research in Virology (37 citations), Infectious Diseases (86 citations), Oncology (109 citations), Cellular and Molecular Neuroscience (58 citations) and Small Animals (23 citations). Mark Zorbas has collaborated with scholars based in United States, Australia and Denmark. Frequent co-authors include Lynn C. Yeoman, David L. Shelton, Susan Hurst, Gary E. Gallick, Stephanie Webber, Bhasker V. Shetty, Matilde Olivé, Mark T. Butt, Amy K. Patick and Xinglin Wu. Their work appears in journals such as Regulatory Toxicology and Pharmacology, Toxicological Sciences, Human & Experimental Toxicology, Antimicrobial Agents and Chemotherapy and Drug Metabolism and Disposition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.